Frank A. Post

Weight Gain Following Initiation of Antiretroviral Therapy: Risk Factors in Randomized Comparative Clinical Trials

Paul E. Sax, Kristine M. Erlandson, Jordan E. Lake et al. · Clinical Infectious Diseases · 2019 · 750 citations · Full text

Public Health, Pharmacotherapy, Clinical Epidemiology +15

Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials

Paul E. Sax, David A. Wohl, Michael T. Yin et al. · The Lancet · 2015 · 598 citations

Pharmacy, Pharmacology, Pharmacotherapy +17

Emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis (DISCOVER): primary results from a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial

Kenneth H. Mayer, Jean‐Michel Molina, Melanie Thompson et al. · The Lancet · 2020 · 424 citations · Full text

Public Health, Pharmacology, Pharmacotherapy +17

Risk Factors and Outcomes for Late Presentation for HIV-Positive Persons in Europe: Results from the Collaboration of Observational HIV Epidemiological Research Europe Study (COHERE)

Amanda Mocroft, Jens Lundgren, Miriam Lewis Sabin et al. · PLoS Medicine · 2013 · 360 citations · Full text

Public Health, Health Sciences, Clinical Epidemiology +10

<i>Mycobacterium tuberculosis</i> Growth at theCavity Surface: a Microenvironment with FailedImmunity

Gilla Kaplan, Frank A. Post, André L. Moreira et al. · Infection and Immunity · 2003 · 350 citations · Full text

Life Sciences, Immunology, Microbiology +15